Related Experiment Video
Updated: May 23, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
GPR56 in cancer progression: current status and future perspective.
1Department of Biomedical Genetics, Department of Dermatology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
Future Oncology (London, England)
|April 21, 2012
Summary
G protein-coupled receptor GPR56 inhibits melanoma progression by regulating VEGF and angiogenesis. Its interaction with tissue transglutaminase in cancer requires further study.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Cell adhesion is crucial in cancer progression, mediated by transmembrane receptors.
- GPR56, a G protein-coupled receptor, acts as an adhesion receptor binding extracellular matrix proteins.
- GPR56 inhibits melanoma progression and regulates VEGF production via a PKCα pathway.
Purpose of the Study:
- To investigate the role of GPR56 in cancer progression.
- To identify extracellular matrix proteins that bind to GPR56.
- To explore the functional relationship between GPR56 and tissue transglutaminase in cancer.
Main Methods:
- Characterization of GPR56 as an adhesion receptor.
- Analysis of GPR56's role in melanoma progression.
- Identification of tissue transglutaminase as a GPR56 binding partner.
Main Results:
- GPR56 inhibits melanoma progression.
- GPR56 regulates VEGF production and angiogenesis.
- Tissue transglutaminase binds to GPR56 and has diverse roles in cancer.
Conclusions:
- GPR56 is an important regulator of melanoma progression and angiogenesis.
- Tissue transglutaminase is the first identified extracellular binding partner of GPR56.
- The precise role of tissue transglutaminase in GPR56-mediated cancer progression remains to be elucidated.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...